The going concern warning combined with the same-day prospectus supplement makes an equity offering imminent and likely at distressed terms. Traders should expect significant dilution — the company needs to raise enough cash to cover at least 6-12 months of operations, which at current burn rates means $15-30M, representing 22-44% of the current market cap. Watch for the pricing of the offering; any discount to market will accelerate downside. The business update (new ARC agreement, NIN installation) is positive but immaterial against the existential liquidity risk.
Price Chart
Executive Summary
Nano-X Imaging reported preliminary Q2 2026 revenue of $4.0-$4.1M (up ~35% YoY from $3.0M), driven by AI/software growth from the Vaso Healthcare IT acquisition. However, cash burned from $60.0M to $31.4M since year-end, and management explicitly states that current cash is insufficient to fund operations for 12 months, raising substantial doubt about the company's ability to continue as a going concern. The filing is bundled with a same-day prospectus supplement under an existing shelf registration (F-3), indicating an imminent capital raise that will likely be highly dilutive given the $68M market cap and urgent cash needs.
Key Facts
- Preliminary Q2 2026 revenue of $4.0-$4.1M vs $3.0M in Q2 2025 (YoY growth ~33-37%)
- Cash, cash equivalents, short-term and long-term restricted deposits fell to $31.4M as of June 30, 2026, from $60.0M at December 31, 2025 (burn of $28.6M in 6 months)
- Management states cash is 'not sufficient to support operations under current operating plans for at least one year' — explicit going concern warning
- Company is evaluating potential impairment charges on long-lived assets and/or goodwill, which could further reduce reported equity
- A prospectus supplement under the existing Form F-3 shelf registration was filed on the same day (July 23, 2026), signaling an imminent capital raise
- AI/software revenue grew to $1.0M (from $0.1M) mainly from consolidation of Vaso Healthcare IT Corp., but hardware revenue was flat at $0.2M
- First Nanox Imaging Network installation completed in Philadelphia; site preparing for first patient scan
- New Nanox.ARC CapEx agreement signed in the US; additional installations expected
- UK reseller agreement signed with Vertec Scientific Ltd. for Nanox.AI Bone solution with minimum annual commitments
Financial Impact
Cash burn of ~$28.6M in H1 2026; at current $68M market cap, an equity offering to cover even 6 months of cash needs would be highly dilutive (potentially 30-50%+ dilution). Revenue growth is modest in absolute terms ($1M increase) and largely acquisition-driven.
Risk Factors
- Imminent dilutive equity offering at potentially distressed pricing
- Going concern risk — cash insufficient for 12 months of operations with no committed financing
- Potential impairment charges that could further reduce book value
- Revenue growth is largely acquisition-driven (Vaso Healthcare IT) rather than organic; hardware revenue flat
- Nasdaq listing risk if market cap continues to deteriorate below compliance thresholds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (NNOX) — Batch item 1 | 0001213900-26-081025 |
| Document: ea0298688-6k_nanox.htm | 0001213900-26-081025 |
| Document: 0001213900-26-081025-index-headers.html | 0001213900-26-081025 |
| Document: 0001213900-26-081025-index.html | 0001213900-26-081025 |
| Document: 0001213900-26-081025.txt | 0001213900-26-081025 |
| 6-K Filing (NNOX) — Batch item 6 | 0001213900-26-081025 |
| Document: ea0298688-6k_nanox.htm | 0001213900-26-081025 |
| Document: 0001213900-26-081025-index-headers.html | 0001213900-26-081025 |
| Document: 0001213900-26-081025-index.html | 0001213900-26-081025 |
| Document: 0001213900-26-081025.txt | 0001213900-26-081025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $0.4100 | awaiting T+20 | — | $0.3384 (+17.46%) |
Oct 16, 2026 10d ago | Press Release | $0.4100 | awaiting T+20 | — | $0.3384 (+17.46%) |
Oct 2, 2026 24d ago | 6-K | $0.6430 | awaiting T+20 | — | $0.3384 (+47.37%) |
Sep 9, 2026 6w ago | 6-K | $0.7800 $0.5950 | ▲ +23.72% | ▲ +25.66% | $0.3384 (+56.62%) |
Aug 18, 2026 10w ago | Press Release | $0.8869 $0.7537 | ▼ −15.02% | ▼ −13.27% | $0.3384 (−61.84%) |
Aug 18, 2026 10w ago | 6-K | $0.8869 $0.7537 | ▲ +15.02% | ▲ +13.27% | $0.3384 (+61.84%) |
Aug 7, 2026 11w ago | 424B5 | $1.06 $0.8298 | ▲ +21.72% | ▲ +21.32% | $0.3384 (+68.08%) |
Aug 4, 2026 12w ago | 144 | $1.07 $0.7859 | ▼ −26.55% | ▼ −25.31% | $0.3384 (−68.37%) |
Jul 28, 2026 12w ago | 144 | $0.8772 $0.8758 | ▲ +0.16% | ▲ +5.18% | $0.3384 (+61.42%) |
Jul 23, 2026 13w ago | 6-K | $0.8962 $0.8599 | ▲ +4.05% | ▲ +7.68% | $0.3384 (+62.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers